Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand
- PMID: 30893381
- PMCID: PMC6426207
- DOI: 10.1371/journal.pone.0214148
Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand
Abstract
Disease-related complications and management are different among patients with thalassemia. This study was aimed to review the prevalence, clinical risk factors for the complications and the management in patients with thalassemia in Thailand. A multicenter cross-sectional study was conducted in patients with thalassemia aged ≥ 18 years old. Thalassemia-related complications and management were reviewed. The clinical parameters significantly associated with the complications were analyzed by logistic regression methods. The prevalence of thalassemia-related complications was 100% in patients with transfusion-dependent thalassemia (TDT) and 58.8% in patients with non-transfusion-dependent thalassemia (NTDT). Advanced age was statistically associated with extramedullary hematopoiesis in both TDT and NTDT patients. Splenectomy was a significant risk factor for pulmonary hypertension in both groups of patients. Severe iron overload started earlier in patients with TDT than NTDT and was associated with diabetes mellitus (adjusted odds ratio (AOR) = 6.2, p-value = 0.02). Disease-related complications are more prevalent in patients with TDT than patients with NTDT. Splenectomy and advanced age were important risk factors for developing major complications in both groups. Early screening and management for specific disease-related complications should be considered in patients with thalassemia according to their clinical risk factors.
Conflict of interest statement
No Novartis or any pharmaceutical company products nor honoraria were used to conduct any of the research as part of this publication. Chuncharunee S has received research funding and honoraria from Novartis Pharmaceuticals, Janssen-Cilag, Roche, and Celgene. Teawtrakul N received honoraria from Novartis and Janssen-Cilag. Siritanaratkul N. received research funding and honoraria from Novartis, Janssen-Cilag, Roche, and Pfizer. The remaining author declares no competing financial interests. There are no patents, products in development or marketed products to declare. This does not alter our adherence to the PLOS ONE policies on sharing data and materials.
Figures



Similar articles
-
Epidemiologic study of major complications in adolescent and adult patients with thalassemia in Northeastern Thailand: the E-SAAN study phase I.Hematology. 2018 Jan;23(1):55-60. doi: 10.1080/10245332.2017.1358845. Epub 2017 Jul 31. Hematology. 2018. PMID: 28759343 Clinical Trial.
-
PREVALENCE AND RISK FACTORS FOR CARDIAC IRON OVERLOAD AND CARDIOVASCULAR COMPLICATIONS AMONG PATIENTS WITH THALASSEMIA IN NORTHERN THAILAND.Southeast Asian J Trop Med Public Health. 2016 Nov;47(6):1335-42. Southeast Asian J Trop Med Public Health. 2016. PMID: 29634199
-
Pulmonary hypertension in non-transfusion-dependent thalassemia: Correlation with clinical parameters, liver iron concentration, and non-transferrin-bound iron.Hematology. 2015 Dec;20(10):610-7. doi: 10.1179/1607845415Y.0000000014. Epub 2015 May 12. Hematology. 2015. PMID: 25964094
-
Morbidities in non-transfusion-dependent thalassemia.Ann N Y Acad Sci. 2016 Mar;1368(1):82-94. doi: 10.1111/nyas.13083. Ann N Y Acad Sci. 2016. PMID: 27186941 Review.
-
Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management.Curr Med Res Opin. 2016;32(1):191-204. doi: 10.1185/03007995.2015.1110128. Epub 2015 Nov 25. Curr Med Res Opin. 2016. PMID: 26479125 Review.
Cited by
-
Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran.J Endocrinol Invest. 2019 Dec;42(12):1467-1476. doi: 10.1007/s40618-019-01072-z. Epub 2019 Jun 21. J Endocrinol Invest. 2019. PMID: 31228105
-
Immune responses in beta-thalassaemia: heme oxygenase 1 reduces cytokine production and bactericidal activity of human leucocytes.Sci Rep. 2020 Jun 24;10(1):10297. doi: 10.1038/s41598-020-67346-2. Sci Rep. 2020. PMID: 32581238 Free PMC article.
-
Natural Antioxidants in Anemia Treatment.Int J Mol Sci. 2021 Feb 13;22(4):1883. doi: 10.3390/ijms22041883. Int J Mol Sci. 2021. PMID: 33668657 Free PMC article. Review.
-
Evaluation of microstructural changes in the brain in transfusion dependent thalassemia patients with advanced magnetic resonance imaging techniques.Neuroradiology. 2024 Oct;66(10):1721-1728. doi: 10.1007/s00234-024-03414-y. Epub 2024 Jul 8. Neuroradiology. 2024. PMID: 38975995 Free PMC article.
-
Impaired neutrophil extracellular trap formation in β-thalassaemia/HbE.Sci Rep. 2022 Feb 4;12(1):1967. doi: 10.1038/s41598-022-06036-7. Sci Rep. 2022. PMID: 35121800 Free PMC article.
References
-
- Thein SL. Genetic modifiers of beta-thalassemia. Haematologica. 2005;90:649–60. - PubMed
-
- Thein SL. The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. Blood Rev. 2012;26 Suppl 1:S35–39. - PubMed
-
- Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26 Suppl 1:S3–6. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical